» Exactech's Management Discusses at Canaccord Genuity Global Growth Conference - Conference Call Transcript
» Navidea Biopharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.
H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.